Diesel exhaust particles (DEP) and their organic constituents modulate the immune system and exacerbate allergic airway inflammation. We investigated the role of DEP extract and associated polycyclic aromatic hydrocarbons (PAHs) on prostaglandin synthesis in endotoxin-activated murine macrophages and in mitogenstimulated fibroblasts. In both macrophages and fibroblasts, DEP extract, phenanthrene, anthracene, phenanthrenequinone, and ␤-napthoflavone inhibit prostaglandin production from endogenous arachidonic acid in response to ligand stimulation. However, DEP extract and PAHs do not block ligand induction of cyclooxygenase-2 (COX-2) protein, either in mitogenstimulated fibroblasts or endotoxin-treated macrophages. Release of total arachidonic acid and total lipid products is not reduced by DEP or PAHs following ligand stimulation of macrophages or fibroblasts. DEP extract and the PAHs inhibit the activity of purified COX-2 enzyme in vitro but do not inhibit COX-1 activity. Thus, DEP and PAHs do not affect ligand-induced COX-2 gene expression, phospholipase activation, or arachidonic acid release in macrophages and fibroblasts but exert their inhibitory effect on prostaglandin production by preferentially blocking COX-2 enzyme activity.
1 account for a significant percentage of the suspended particulate matter in the atmosphere. DEP consist of an inert carbonaceous core and a wide variety of organic compounds composed of unburned petrochemicals that include polycyclic aromatic hydrocarbons (PAH), halogenated aromatic hydrocarbons, and redox-active quinones (2) . Phenanthrene (PE) is a major constituent of DEP comprising 6% of the total organic extract; as a family, PEs constitutes 52% of the total PAH found in DEP (3) .
DEP can cause asthma-like conditions such as infiltration of inflammatory cells, proliferating goblet cells, increased mucus secretion, respiratory resistance, and airway constriction (4) . Human studies and animal models of allergic rhinitis and asthma have shown that DEP can have both short and long term effects on the immediate hypersensitivity to allergic response (5) . DEP have the ability to induce IgE responses, either by acting directly on B-cells or indirectly by enhancing cytokine production. By both initiating and enhancing IgE production, DEP may be of importance in the increased incidence of allergic airway disease (6) . DEP-stimulated human airway epithelial cells release inflammatory cytokines and mediators such as IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and the soluble form of intercellular adhesion molecule-1 (ICAM-1) in vitro (7) . ICAM-1 has been suggested to play a critical role in the attachment and migration of immune inflammatory cells to airway mucosa (8) . Among the other cell types involved in allergic inflammation, DEP also affect the functions of macrophages, eosinophils, epithelial cells, and mast cells (2) . DEP also act as adjuvant, enhancing mucosal immune responses to other agents (9) . PE and anthracene (ANT), both components of DEP, also enhance antigen-specific IgE and IgG1 production (10) .
In 1977, Levine and Hong (11) reported that PE, ANT, and benzoflavone blocked prostaglandin production from transformed mouse and human fibroblasts and canine kidney cells. The committed step in prostaglandin biosynthesis, the conversion of free arachidonic acid to prostaglandin H 2 (PGH 2 ) , is catalyzed by the cyclooxygenase (COX) enzyme(s). PGH 2 is subsequently converted to a variety of eicosanoids depending on the cell-specific expression of alternative enzymes that utilize PGH 2 as substrate. Two isoforms of COX exist (12) . COX-1 is constitutively expressed in most cell types and is responsible for "housekeeping functions." COX-2 is normally undetectable in most tissues but can be induced in many different cell types by a wide variety of stimuli that include proinflammatory and mitogenic agents (12) . Prostaglandins promote inflammation by increasing vascular permeability (13) and vasodilatation (14) and by directing cellular migration into the site of inflammation through prostaglandin-mediated production and release of proinflammatory cytokines (15) .
Nonsteroidal anti-inflammatory drugs block the ability of the cyclooxygenases to convert arachidonic acid to PGH 2 . Exposure to indomethecin, a classic nonsteroidal anti-inflammatory drug inhibitor of both COX-1 and COX-2, during airway sensitization exacerbates allergic airway inflammation in ovalbumin (OA)-sensitized mice (16) . Allergic lung responses are also exacerbated in COX-1-and COX-2-deficient mice using a similar OA immunization/challenge model (17) . Thus, both pharmacologic (16) and genetic (17) studies suggest that endogenous COX products might limit allergic lung inflammation and that inhibition of cyclooxygenase activity might exacerbate allergic lung responses.
The observation that PE and ANT can block prostaglandin synthesis in transformed fibroblasts (11) was reported long before the discovery of COX-2. We thought it possible that one mechanism by which DEP exacerbates allergic airway inflammatory responses might be via the modulation of prostaglandin production. In the present study, we investigate the effects of DEP extract and a number of PAHs on prostaglandin synthesis, COX-2 expression, and cyclooxygenase activity in unstimulated and ligand-stimulated murine fibroblasts and macrophages.
EXPERIMENTAL PROCEDURES
Materials-Dulbecco's modified Eagle's medium and phosphate-buffered saline were supplied by Invitrogen. PE, phenanthrenequinone (PQ), ANT, ␤-napthoflavone (BNF), bovine serum albumin, bacterial lipopolysaccharide (LPS), hematin, and iodine crystals were from Sigma. Arachidonic acid, PGE 2 , PGF 2␣ , ovine COX-1, ovine COX-2, and polyclonal rabbit anti-COX-2 antibody were purchased from Cayman Chemicals. The screening kit for COX-1 and COX-2 inhibitors (the colorimetric COX (ovine) screening assay kit) and the COX-2-and COX-1-specific inhibitors DuP-697 and SC-560 were also purchased from Cayman Chemicals. NS-398 was from Biomol. Platelet-derived growth factor (PDGF)-BB was from R&D Chemicals. [ 3 H]Arachidonic acid (80 Ci/mM) was from PerkinElmer Life Sciences. Phenol and silica gel TLC plates were purchased from EM Sciences. Enzyme-linked immunosorbent assay kits for PGE 2 assay and ECL reagent were purchased from Amersham Biosciences. The polyclonal anti-14 -3-3 antibody was from Santa Cruz Biotechnology. DEP extract was supplied by Dr. Andre Nel (UCLA) (2) .
Cell Culture and Treatment-RAW 264.7 murine macrophage cells were maintained in endotoxin-free Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in 5% CO 2 as described previously (18) . NIH 3T3 fibroblasts were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum in 5% CO 2 as described previously (19) .
Inducers and Inhibitors-PE, PQ, ANT, BNF, and DEP extract were dissolved in Me 2 SO. Before use, the chemicals were diluted in culture medium to the indicated concentrations. The final Me 2 SO concentration in culture medium was 0.005%. LPS was dissolved in phosphate-buffered saline and added to the culture medium at a final concentration of 10 ng/ml. PDGF was prepared in 4 mM HCl and diluted with medium to a final concentration of 10 ng/ml.
Prostaglandin Induction-RAW 264.7 macrophages or NIH 3T3 fibroblasts were plated in 12-well culture plates (1 ϫ 10 4 cells/well). The following day, the cells were washed with phosphate-buffered saline and shifted to medium containing 0.5% serum overnight. Cells were treated with inducers and PAHs or DEP extract concurrently and incubated for 6 h as indicated in individual experiments. The supernatants were collected and assayed for PGE 2 by enzyme-linked immunosorbent assay (18) .
Immunoblot Analysis-At the end of experiments, RAW 264.7 macrophages and NIH 3T3 fibroblasts were washed with cold phosphatebuffered saline and lysed in passive lysis buffer (Promega). Cell extracts were subjected to electrophoresis, and Western blot analysis was performed as described previously (18) . The nitrocellulose membrane was incubated with rabbit polyclonal anti-COX-2 antibody or anti-14 -3-3 antibody, used at 1:1000 dilutions, followed by horseradish peroxidaseconjugated goat anti-rabbit antibody at 1:4000 dilutions and developed with ECL chemiluminescence reagents.
Arachidonic Acid/Arachidonic Acid Product Release-RAW 264.7 macrophages and NIH 3T3 fibroblasts were plated in 6-well culture plates. The following day, cells were labeled with [ 3 H]arachidonic acid (1.5 Ci/well). Forty-eight h later, the cultures were washed and treated with the PAHs or with DEP extract along with inducing ligands in medium containing 0.1% bovine serum albumin. Six h later, lipids were extracted from cell culture media and analyzed, as described previously (18, 20) , for total arachidonic acid-derived products, arachidonic acid, and prostaglandins. Briefly, total radioactivity in a portion of each lipid sample was determined to measure total arachidonic acid-derived products. Samples of the isolated lipids were spotted on TLC plates, and chromatography was performed in a solvent system containing CHCl 3 :MeOH:acetic acid:H 2 O at 90:8:1:0.8. A mixture of lipid standards was run and visualized with iodine vapor. Spots corresponding to arachidonic acid, PGE 2 , and PGF 2␣ were collected, and radioactivity was determined in a scintillation counter.
COX-1 and COX-2 Inhibition Assays-The ability of DEP and the PAHs to inhibit COX-1 and COX-2 enzyme activity was first examined using the Cayman COX-1 and COX-2 colorimetic screening kit. This assay analyzes the peroxidase activity of the enzymes using N,N,NЈ,NЈ-tetramethylphenylenediamine as the reducing co-substrate. The kit includes purified ovine COX-1 and COX-2 enzymes. SC-560 was used as the positive control for COX-1 inhibition; DuP-697 was used as the positive control for COX-2 inhibition. The DEP and PAHs were dissolved in Me 2 SO and diluted in the assay buffer before use. The assays were run according to the manufacturer's instructions.
The effect of DEP and the PAHs on the bisoxygenase reaction of COX-1 and COX-2 was also assayed by measuring oxygen consumption with a polarographic electrode (21) Cyclooxygenase activity was measured by monitoring O 2 consumption in a fiber optic spectrofluorimeter using a Foxy AL-300 probe (Ocean Optics, Dundein, FL). Purified COX-1 or COX-2 enzymes (60 units) were incubated with the presumptive inhibitors for 10 min at 37°C. Reactions were initiated by the addition of the enzyme/inhibitor mixture and arachidonic acid (to a final concentration of 100 M) to the reaction buffer (0.1 M Tris-HCl, pH 7.8, 5 mM EDTA, 2 mM phenol, 1 M hematin) (22, 23) . O 2 consumption was continuously measured; initial slopes were used to determine the rate of oxygen consumption. SC-560 was used as the positive inhibitor control for COX-1 and NS-398 as the positive inhibitor control for COX-2.
RESULTS

DEP Extract Inhibits Prostaglandin Production in Endotoxin-stimulated
Macrophages-Macrophages are one of the key players in airway allergic responses (24) . Hence, we first examined the effect of DEP extract on prostaglandin production in murine macrophages. RAW 264.7 macrophages were treated with LPS (10 ng/ml). A concentration series of DEP extract was added along with LPS. After 6 h, medium samples were collected and assayed for PGE 2 . A 50% reduction in LPS-induced prostaglandin synthesis was observed with 50 ng/ml DEP (Fig.  1A) . Vehicle (Me 2 SO) had no inhibitory effect on prostaglandin synthesis (data not shown).
Phenanthrene Inhibits Endotoxin-stimulated Prostaglandin Production in Macrophages-Phenanthrene is one of the major components of DEP extract (25) . We next examined the effect of PE on prostaglandin production in RAW 264.7 macrophages. The cells were treated with LPS (10 ng/ml) in the presence of increasing concentrations of PE (10 -250 nM). After 6 h, medium samples were collected and analyzed for PGE 2 production. PE is an effective inhibitor of endotoxin-induced PGE 2 accumulation (Fig. 1B) ; 50% inhibition of endotoxin-induced PGE 2 accumulation occurs between 50 and 100 nM PE.
Other Polycyclic Aromatic Hydrocarbons Also Block Prostaglandin Production in Macrophages-A variety of other PAHs are also present in DEP extracts (3) . We compared PQ, ANT, and BNF with PE to determine the relative efficacy of various PAHs for inhibition of prostaglandin induction in endotoxintreated macrophages. RAW 264.7 macrophages were treated with 100 nM of each PAH along with endotoxin (10 ng/ml). At the end of 6 h of incubation, the supernatants were collected for PGE 2 assay. Each PAH is an effective inhibitor of endotoxinstimulated PGE 2 production in RAW 264.7 macrophages (Fig.  1C) . Dose-response curves suggest that PQ may be a slightly better inhibitor than the other PAHs (data not shown), but differences in inhibitory activity among the various PAHs are not striking.
DEP Extract and Polycyclic Aromatic Hydrocarbons Also Inhibit Prostaglandin Production in Mitogen-stimulated Fibro-
blasts-Prostaglandin production in response to ligand stimulation is usually dependent on COX-2 induction (12, 26). The induction pathway leading to COX-2 expression is similar in fibroblasts (27) , mast cells (28), and osteoblasts (29) but differs from these cell types in endotoxin-stimulated macrophages (30) . To determine whether the inhibition of prostaglandin production by DEP extract and PAHs is unique to ligandstimulated macrophages, we examined the induction of PGE 2 in mitogen-treated fibroblasts.
Quiescent, non-dividing NIH 3T3 cells were induced with PDGF (10 ng/ml) in the presence of increasing concentrations of DEP extract. As observed for macrophages, DEP extract effectively blocks ligand-induced prostaglandin production in mitogen-stimulated fibroblasts ( Fig. 2A) . PE (Fig. 2B ) and other PAHs (PQ, BNF, ANT; Fig. 2C ) are also potent inhibitors of PDGF-induced PGE 2 accumulation in fibroblasts.
Diesel Exhaust Particle Extract and Phenanthrene Do Not Block Ligand-induced COX-2 Gene Expression, Either in En-
dotoxin-stimulated Macrophages or in Mitogen-treated Fibroblasts-DEP and extracts of these particles are able to regulate the expression of a number of genes (31) . Ligand-induced expression of COX-2 message and protein are necessary for both endotoxin-induced PGE 2 synthesis in macrophages and mitogen-stimulated PGE 2 production in fibroblasts (18) . One possible mechanism by which DEP extract and PAHs block prostaglandin production in ligand-treated cells might, therefore, be by preventing the induction of COX-2 mRNA or protein expression.
RAW 264.7 macrophages were treated with LPS (10 ng/ml), and NIH 3T3 fibroblasts were treated with PDGF (10 ng/ml). For each cell type, various concentrations of either DEP extract or PE were added concomitantly with the inducer. After 6 h, cells were harvested, and protein extracts were analyzed by Western blot for COX-2 expression in macrophages (Fig. 3 , upper panel) and in fibroblasts (Fig. 3, lower panel) . Surprisingly, at all concentrations tested, neither DEP nor PE had any effect on COX-2 expression. Thus, PE and DEP must inhibit ligand-stimulated prostaglandin production, both in macrophages and in fibroblasts, by a mechanism that does not interfere with COX-2 gene expression. DEP and PE, by themselves, did not induce COX-2 expression in NIH 3T3 fibroblasts or RAW 264.7 macrophage (data not shown).
Diesel Exhaust Particle Extract and Polycyclic Aromatic Hydrocarbons Do Not Block Arachidonic Acid Release from Endotoxin-treated Macrophages or Mitogen-treated Fibroblasts-
DEP extract and PAHs inhibit ligand-induced prostaglandin production in macrophages and fibroblasts but do not inhibit ligand-induced COX-2 induction. DEP extract and PAHs may also influence mitogen-induced or endotoxin-stimulated arachidonic acid release from endogenous stores. To investigate this possibility, we measured total arachidonic acid-derived lipid release, free arachidonic acid release, PGE 2 produc- tion, and PGF 2␣ production from cellular phospholipid pools in which the arachidonic acid was radioactively labeled.
RAW 264.7 macrophages and NIH 3T3 fibroblasts membrane phospholipids were labeled with [ 3 H]arachidonic acid (18) . Cells were then treated with ligand (LPS or PDGF, respectively) and DEP extract or PAHs. Lipids were subsequently extracted from the media, and the amounts of radioactive total lipids, arachidonic acid, PGE 2 , and PGF 2␣ present in the media were determined by TLC. Total radioactive lipid release in response to ligand stimulation was unaffected by the presence of either DEP extract or any of the PAHs tested (Fig.  4) . DEP extract and PAHs modestly increased the level of arachidonic acid found in the medium of ligand-stimulated macrophages and fibroblasts (Fig. 5) . Clearly, DEP extract and PAHs do not prevent phospholipase activation and arachidonic acid release in endotoxin-treated macrophages or mitogenstimulated fibroblasts.
Ligand-stimulated production of both radioactive PGE 2 and PGF 2␣ could also be demonstrated by TLC of media collected from the endotoxin-treated macrophages and PDGF-treated fibroblasts (data not shown). The presence of DEP extract or PAHs reduced the production of radioactive PGE 2 and PGF 2␣ . The inhibition in PGE 2 synthesis from endogenous radioactive arachidonic acid stores, determined by TLC of radioactive lipids, is consistent with the observations made using the PGE 2 enzyme-linked immunosorbent assay (Figs. 1 and 2) . The inhibition of PGF 2␣ production suggests that it is COX-2 inhibition, and not inhibition of PGE 2 synthase, that is responsible for the inhibition of prostaglandin accumulation by DEP and the PAHs.
Diesel Exhaust Particle Extract and PAHs Preferentially Inhibit COX-2 Enzyme Activity in Vitro-DEP extract and
PAHs block ligand-induced prostaglandin synthesis in macrophages and fibroblasts but do not prevent COX-2 induction or arachidonic acid release. The simplest explanation to account for inhibition of COX-2-dependent prostaglandin production by DEP and PAHs in ligand-treated macrophages and fibroblasts would be that these compounds directly inhibit the COX-2 enzymatic activity. Purified ovine COX-1 and COX-2 were used to determine whether DEP extract and the PAHs could directly inhibit the activity of these enzymes in vitro.
We first examined the peroxidase activity of COX-1 and COX-2 in the presence of a COX-1 inhibitor, a COX-2 inhibitor, DEP, and several PAHs. In control experiments, DuP-697 inhibited COX-2 activity (IC 50 of ϳ80 nM) but had no effect on COX-1 activity, even at 400 nM (Fig. 6) . In contrast, SC-560 inhibited COX-1 activity (IC 50 of ϳ15 nM) but was unable, even at 50 nM, to inhibit COX-2. The inhibitory activity of DEP extract was examined over a 10 -500 ng/ml concentration range. The inhibitory activities of the PAHs were examined over concentration ranges of 10 -400 nM. DEP and the PAHs (PE, BNF, and ANT) used in this study all inhibit the peroxidase enzymatic activity of purified COX-2 but have no effect on COX-1 activity. The IC 50 values for COX-2 peroxidase inhibition by DEP, PE, BNF, and ANT are 110 ng/ml, 130 nM, 160 nM, and 195 nM, respectively. In summary, DEP and associated PAHs inhibit COX-2 peroxidase enzymatic activity but have no
FIG. 3. DEP extract and PE do not block ligand-induced COX-2 expression in RAW 264.7 macrophages or NIH3T3 fibroblasts.
Upper panel, Raw 264.7 cells were treated with LPS (10 ng/ml) with or without DEP extract (upper lanes) or PE (lower lanes). Six h later, cells were harvested, and protein extracts were analyzed by 10% SDS-PAGE and Western blotting with anti-COX-2 antiserum. Anti-14 -3-3 was analyzed as a loading control. Lower panel, NIH 3T3 cells were stimulated with PDGF (10 ng/ml) with or without DEP (upper lanes) and PE (lower lanes) for 6 h and then lysed and assayed for COX-2 production by Western blot analysis. Anti-14 -3-3 was analyzed as a loading control. C, control untreated cells.
FIG. 4. DEP extract and phenanthrene do not block total arachidonic acid-derived product release from LPS-treated RAW 264.7 macrophages or PDGF-stimulated NIH 3T3 fibroblasts. In A and B, RAW 264.7 cells were labeled with [
3 H]arachidonic acid as described under "Experimental Procedures." After washing, the cells were treated with LPS (10 ng/ml) in the presence or absence of DEP extract (100 ng/ml) or PE (100 nM). After 6 h, lipids were extracted from the medium, and radioactivity was measured by scintillation counting. In C and D, NIH 3T3 cells were labeled with [ 3 H]arachidonic acid. After washing, the cells were treated with PDGF (10 ng/ml) in the presence or absence of DEP extract (100 ng/ml) or PE (100 nM). After 6 h, lipids were extracted from the medium, and radioactivity was measured by scintillation counting. Data are expressed as percentage of the maximal cpm of 3 H present in the medium and are the averages Ϯ S.D. from triplicate plates.
effect on COX-1 peroxidase activity at comparable and higher concentrations.
It is possible that DEP and the PAHs might inhibit the oxidation of the peroxidase substrates directly or indirectly inhibit cyclooxygenase activity by preventing oxidative activation of the COX-2 enzyme. Consequently, we also assessed the effect of DEP and the PAHs on the bisoxygenase reaction of COX-1 and COX-2 by measuring oxygen consumption with a polarographic electrode (22, 23) . The COX-1 inhibitor SC-560 inhibits COX-1 cyclooxygenase activity ϳ70% at 200 nM concentration but has no inhibitory effect on COX-2 activity (Fig.  7) . Similarly, the COX-2 inhibitor NS-398 (500 nM) inhibits COX-2 cyclooxygenase activity ϳ60% but has no effect on COX-1 enzyme activity. DEP extract (500 ng/ml) and PE (500 nM) do not inhibit COX-1 bisoxygenase enzyme activity. In contrast, both DEP extract and PE, at these same concentrations, effectively inhibit COX-2 cyclooxygenase activity. In summary, using assays for both the peroxidase activity and the bisoxygenase activity of COX-1 and COX-2, DEP extract and PE are preferential inhibitors of purified COX-2 and demonstrate little, if any, inhibition of COX-1 enzyme activity.
DISCUSSION
Diesel exhaust particles are one of the major air pollutants in urban areas. DEP can reach the pulmonary alveoli during inhalation of contaminated air and cause pulmonary tumors, edematous change, focal chronic alveolitis, and allergic airway disorders in experimental animals (32). Sagai and co-workers (4, 33) have demonstrated increased allergic airway hyperreactivity responses in mice challenged with OA in the presence of either intratrachially administered DEP (4) or inhaled DEP (33) . DEP may participate in allergic inflammatory processes by increasing production of both IgE and TH2 cytokines in both humans and animals challenged by allergens (34) . In addition, production of reactive oxygen species has been proposed to play a role in the activity of DEP and their PAH constituents in airway allergic adjuvant responses (35) . Macrophages are likely to be involved in the adjuvant activity of DEP since DEP can increase CD86 expression in macrophages both in vivo and in vitro (9) . As a long term effect of this adjuvant action on airway hyperreactivity, DEP may play a role in the increased prevalence of asthma as observed in Japan (36) and other industrialized environments.
Recent studies with murine models suggest that eicosanoids may play a substantive role in modulating allergic airway inflammation. 5-lipoxygenase knockout mice demonstrate reduced airway hyperresponsiveness and eosinophil infiltration in allergen-induced airway inflammation (37) . These data are not surprising given the powerful beneficial effects of leukotriene inhibitors and leukotriene receptor antagonists in allergic airway disease. Peebles et al. (16) exposed mice to continuous systemic indomethacin, an inhibitor of both COX-1 and COX-2, during an OA sensitization/inhalation protocol. PGE 2 levels in lung lavages were reduced, and leukotriene levels were elevated. Both IL-5 and IL-13 levels were increased in lung extracts following OA aerosol treatment in the presence of indomethacin, suggesting that inhibition of prostaglandin production results in an elevated allergic response. Methacholine challenge of indomethacin-treated mice in this OA sensitization/inhalation protocol produced significantly greater airway hyperresponsiveness than in control animals. Using the same animal model, both COX-1-and COX-2-deficient mice also demonstrate an exacerbated allergic lung response (e.g. lung histopathology and decreased respiratory compliance) 3 H]arachidonic acid as described under "Experimental Procedures." After washing, the cells were treated with LPS (10 ng/ml) in the presence or absence of DEP extract (100 nM) or PQ (100 nM). After 6 h, lipids were extracted from the medium, and radioactive arachidonic acid was measured by TLC as described previously (18, 20) . In C and D, NIH 3T3 cells were labeled with (17). Our data demonstrating that DEP extract and several of its organic components can prevent COX-2-dependent prostaglandin production in activated macrophages is consistent with the idea that COX-2 products may limit allergic lung inflammation. Moreover, shunting of arachidonic acid released by ligand stimulation in the presence of DEP components may shift eicosanoid metabolism toward leukotriene production in appropriate cells (e.g. mast cells, endothelial cells), provoking increased airway hyperreactivity. It seems likely that modulation of eicosanoid activity may be an additional important mechanism by which DEP and their constituents modify airway inflammation.
DEP, DEP extract, and several of the PAH components of DEP extract can modulate the expression of a variety of genes. Probably the most well studied is IgE. Both DEP extracts and phenanthrene can enhance IgE production directly in B-cells (3, 38) and act as an adjuvant for IgE production in antigenstimulated cells (39, 40) . DEP, organic extracts of DEP, and benzo[␣]pyrene (B[␣]P) can induce IL-8 expression in epithelial cells (7) . Heme oxygenase-1 can be induced in RAW 264.7 cells, the same macrophage cell line we use in these studies, by DEP extract and by aromatic and polar DEP fractions (41) . In a recent microarray analysis, 207 arrayed stress-induced genes were surveyed with cDNAs prepared from lungs of control rats and lungs from rats instilled with DEP. The expression of at least eight genes, including cyclin D1, MAPKAP2, and the multidrug resistance gene, were significantly associated with DEP exposure (31) .
Given the prior literature demonstrating the effects of DEP and its components on gene expression (see above), the regulatory characteristics of the COX-2 gene, and our observation that DEP and associated PAHs can block ligand-induced prostaglandin synthesis in fibroblasts and macrophages, we thought that DEP and the various PAHs might inhibit COX-2-dependent prostaglandin production in endotoxin-treated macrophages and mitogen-treated fibroblasts by regulating COX-2 gene expression. Surprisingly, however, neither PDGFnor LPS-induced COX-2 expression is at all modulated by DEP or the component PAHs. Moreover, the effects of DEP extract and PAHs on prostaglandin production in stimulated fibroblasts and macrophages are in the nanomolar range, whereas micromolar PAH concentrations are required to modulate gene expression in many of the systems discussed above.
Although Levine and Hong (11) reported that a number of PAH compounds could inhibit prostaglandin production by transformed fibroblasts, B[␣]P is able to induce COX-2 expression in several contexts (42, 43 (42) and oral epithelial cells (43) .
To block ligand-induced prostaglandin synthesis in macrophages and fibroblasts, DEP and its constituents must inhibit some component other than induced COX-2 gene expression. Our dose-response studies suggested that it is COX-2-dependent prostaglandin synthesis that is blocked by DEP/PAHs; the level of inhibition of PGE 2 production never falls below the unstimulated control. Prostaglandin production from unstimulated macrophages and fibroblasts is unaltered by DEP/PAHs, both from endogenous and exogenous arachidonic acid (data not shown), suggesting that these agents do not affect COX-1-dependent prostaglandin synthesis. These suggestions were confirmed by in vitro analysis of the effects of DEP and the PAHs on both the peroxidase and bisoxygenase enzyme activities of purified COX-1 and COX-2; these compounds are preferentially able to inhibit the enzymatic activity of COX-2 versus COX-1. DEP extract/PAHs do not block ligand-stimulated arachidonic acid release from membrane phospholipids, suggesting that the mechanism by which these agents inhibit ligand-induced, COX-2-dependent prostaglandin production is predominately due to their ability to inhibit COX-2 enzyme activity.
Inhibition of prostaglandin synthesis, either by interfering with phospholipase-mediated release of membrane-bound arachidonic acid or by interfering with COX-mediated conversion of free arachidonic acid to prostaglandin, is a major target for pharmacological research. The classic nonsteroidal antiinflammatory drugs such as aspirin, indomethecin, and ibuprofen inhibit the enzymatic activity of both COX-1 and COX-2. The new class of COX-2-specific inhibitors, e.g. NS-398 (12), celecoxib (Celebrex) (45) , and rofecoxib (Vioxx) (46), inhibit COX-2-dependent prostaglandin production but not COX-1-dependent prostaglandin production. To be effective, biologically FIG. 7 . DEP extract and phenanthrene inhibit purified COX-2 bisoxygenase enzyme activity but not COX-1 bisoxygenase activity. The cyclooxygenase activity of purified COX-1 and COX-2 enzymes, in the presence or absence of the presumptive inhibitors, was determined by measuring the initial rate of oxygen consumption, as described under "Experimental Procedures." The relative enzyme activity was determined by comparing the slopes of the curves in the presence of the inhibitors with the initial rate of oxygen consumption for the corresponding enzymes, COX-1 and COX-2, setting these values to 100%. Data are the means Ϯ S.E. from three separate experiments.
active agents, PAHs usually require metabolic activation and often co-valently modify target proteins (47) . However, we find that the COX-2 present in endotoxin-stimulated macrophages can convert exogenous arachidonic acid to PGE 2 after washing away the inhibitory effect of DEP extract or PE (data not shown), suggesting that co-valent modification and irreversible inhibition of COX-2 may not be occurring with the PAHs. It will be of great interest to compare and contrast the mechanisms by which these PAHs and the new COX-2-specific pharmaceuticals inhibit COX-2 enzyme activity.
